Genmab — November 2012
-
Men når de siger flere phase III studier nu her. Tror du så alle sammen bliver som monoterapi?? de kan vel ikke starte phase III i revlimid og velcade kombi før de har phase I/II resultaterne derfra?
-
@sukkeralf hvilken browser?
-
http://finance.yahoo.com/news/smaller-faster-clinical-trials-considered-122000062.html lidt hurtigere vej til approval for dara
-
David sagde endda ordret. "relevant milestones in the next years" da der blev spurgt til om den var backloadet eller frontloadet
-
ASH abstracht er klar nu: Herunder spændnede Daratumumab data: https://ash.confex.com/ash/2012/webprogram/start.html#srch=words|daratumumab|method|and|pge|1|byDayany|any|bySymposiumany|any
-
Taken together, these results suggest that DARA may be a promising therapeutic agent both for MCL, FL and CLL, in which DARA exerts its effects mainly via ADCC and for CLL also via inhibition of migration of tumor cells. Interestingly, the cytotoxic activity of DARA by ADCC could be further augmented by addition of lenalidomide in these three models.
-
-
Og så har jeg lige fået en mail fra genmab. jeg var sq hurtigere end dem
-
Det ser faneme lovende ud
-
nu kan jeg ikke lide at sige det. Men det kunne blive større end arzerra
-
Aka. Husker du hvad jeg skrev for 3 måneder siden? at skulle jeg vælge mellem O og D så tog jeg D.
-
Ja og der troede jeg du var idiot
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind